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Abstract
Cryopreservation of ovarian tissue and in vitro follicle maturation are two emerging techniques for
fertility preservation, especially in cancer patients. These treatment regimes are opening up more
options and allow for more suitable choices to preserve fertility according to the patient's specific
circumstances. If these technologies are to become widely accepted, they need to be safe, easy to
perform and must obtain favorable results. The generation of healthy eggs with the normal genetic
complement and the ability to develop into viable and healthy embryos requires tight regulation of
oocyte development and maturation. Novel freezing techniques such as vitrification, along with
whole ovary cryopreservation and three-dimensional follicle cultures, have shown favorable
outcomes. The scope of this article is to take a comprehensively look at the challenges still faced
in order for these novel technologies to be routinely employed with the aim of successful fertility
preservation.
Background
Despite the availability of several options for fertility pres-
ervation in patients experiencing premature ovarian fail-
ure (POF) due to chemo- or radiotherapy, embryo
cryopreservation remains the only established method of
preserving fertility, according to The Ethics Committee of
the American Society for Reproductive Medicine (ASRM)
[1,2]. This may not be the most appropriate strategy as
most patients are not able to postpone cancer treatment to
undergo a cycle of ovarian stimulation. Furthermore, the
patient is required to be of pubertal age and to have a part-
ner or make use of donor sperm, rendering this method
not suitable to a large percentage of these patients.
The remaining options are either experimental or have
not been fully evaluated and thus can not be proposed to
patients at this time [3]. Cryopreservation/transplantation
of ovarian tissue and in vitro maturation (IVM) of follicles/
oocytes are two such emerging techniques. The aforemen-
tioned treatment regimes are opening up more alterna-
tives and allow for more suitable choices to preserve
fertility according to the patient's specific situation. For
these technologies to be recognized and carried out rou-
tinely, they must be safe, easy to perform and deliver suc-
cessful results. As these technologies are still quite novel,
the goal of this article is to offer an in-depth look at the
challenges that must be overcome with the cryopreserving
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and transplanting of ovarian tissue as well as the IVM of
follicle and oocyte techniques to ultimately lead to suc-
cessful fertility preservation.
Cryopreservation and transplantation of ovarian 
tissue
Ovarian tissue cryopreservation and transplantation is
still an experimental procedure for preserving fertility in
woman faced with failure of reproductive functions. This
technique allows for completion of medical therapy to
treat the primary medical disorder with, for example,
gonadotoxic drugs. Ovarian tissue can be harvested at
laparoscopy or laparotomy by performing several ovarian
biopsies, or a partial, uni- or bilateral oophorectomy and
cryopreserved. The extirpated and cryopreserved ovarian
tissue subsequently can be autotransplanted upon com-
pletion of the medical therapy and after the patient is in
remission. It furthermore can serve as a source of follicles
for IVM.
There are various advantages of ovarian tissue cryopreser-
vation (see Figure 1). Firstly the tissue can be obtained
without delay since there is no need for ovarian stimula-
tion; while no partner is required for male gamete dona-
tion at the time of tissue harvesting. These procedures
offer the advantages of allowing for resumption of repro-
ductive and endocrine function (obviating the need for
hormone replacement therapy) and avoiding immuno-
suppressant medications by performing autotransplanta-
tion. Ovarian tissue cryopreservation also may be a more
viable alternative to cryopreservation of oocytes or
embryos, particularly for pediatric cancer patients. The
disadvantages of ovarian tissue cryopreservation are that it
requires surgical procedures for tissue harvesting and
transfer and there have been only a few pregnancies
world-wide. It is also not an option for women with ovar-
ian cancer as the risk of reintroducing malignant cells into
cancer patients by autografting ovarian cortical fragments
is one main concern. An alternative is isolation of intact
Graafian follicles or pre-antral follicles from freeze-
thawed ovarian tissue and re-transplantation. However,
isolation of follicles by either mechanical or enzymatic
means is cumbersome, especially from human ovaries
having fibrous tissues. It is less clear whether cryopre-
served ovarian tissue should be utilized in women who
have an estrogen-dependent cancer.
Cryopreservation techniques
Martinez-Madrid et al. described a cryopreservation proto-
col using a passive cooling device for an intact human
ovary with its vascular pedicle. This protocol showed high
survival rates of follicles (75.1%), small vessels and
stroma, and a normal histological structure in all the ovar-
ian components after thawing [4]. In a follow-up study,
Martinez-Madrid  et al. [5] compared fresh to cryopre-
served-thawed whole human ovaries with their vascular
pedicle, assessed according to ultrastructure and apopto-
sis. They detected no significant differences in DNA strand
breaks by TUNEL, immunohistochemistry, or activation
of active caspase-3 after thawing. Also, no discernible
ultrastructural alterations were encountered in these fro-
zen-thawed ovaries as assessed by transmission electron
microscopy. These findings are further evidence that their
present freeze-thawing protocol [4] does not cause signif-
icant injury to human ovaries and may be a suitable tech-
nique to cryopreserve whole ovaries until transplantation.
Cryopreservation and transplantation of ovarian tissues Figure 1
Cryopreservation and transplantation of ovarian tissues.
 
Figure 1: Cryopreservation and transplantation of ovarian tissues 
Advantages 
Immediate harvesting (can start treatment without delay) 
No male partner/gamete donor needed 
Allow for complete gonadotoxic and or ionizing radiation treatment without exposure 
Resume endocrine function 
Resume and preserve reproductive function 
Suitable for prepubertal girls 
Disadvantages 
Requires surgical procedures for tissue harvesting and transfer 
Possibility of reintroducing malignant cells 
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Recently, several research groups also have assessed intact
ovarian tissue cryopreservation and transplantation effi-
ciency in animal models. Bedaiwy et al. [6] have shown
that an intact sheep ovary can survive cryopreservation-
thawing insults with reasonable tissue viability. The grafts
were perfused via the ovarian artery with the cryoprotec-
tive mixture using the Horizon® Nxt Modular Infusion
System (B. Braun Medical, Inc., Bethleham, Pa.) to main-
tain a flow rate at 1.3 mL/min with continuous replenish-
ment of the reservoir. The researchers conclude that
perfusion of the cryoprotectant through the vascular chan-
nel and autotransplantation of an intact, frozen-thawed
ovary with microvascular anastomosis is technically feasi-
ble with good short-term results. In a further study
Bedaiwy et al. [7] compared cryopreserved-thawed intact
ovaries with ovarian cortical strips from tissue obtained
from women undergoing bilateral oophorectomy. One of
the harvested ovaries was sectioned and cryopreserved (by
slow freezing) as ovarian cortical strips (1.0 × 1.0 × 5.0
mm), while the other ovary was cryopreserved intact with
its vascular pedicle. After thawing 7 days later results were
comparable thereby proving that using human intact ova-
ries, cryoperfusion and cryopreservation of the entire
human ovary can be achieved with the maintenance of
excellent viability of the superficial and the deeper tissues
using a slow-freezing protocol. Cryopreservation injury
was associated with neither significant alteration in the
expression pattern of Bcl-2 and p53 proteins in the ovar-
ian tissues nor significant follicular damage.
Based on the newly developed technology of directional
freezing (multi-thermal gradient), which is said to freeze
biological samples at a very low and accurate cooling rate
[8] and control the ice crystal morphology, Arav et al. [9]
studied the transplantation efficiency of frozen-thawed,
intact sheep ovaries by artery and vein anastomosis.
Whole sheep ovaries, comprising the follicles and blood
vessels, survived cryopreservation, and ovarian activity
was seen as early as 2 months after transplantation. In
addition, magnetic resonance imaging has shown that
blood vessels were intact and that normal blood flow to
the transplant had resumed. Their study shows that imme-
diate and long-term hormonal restoration and normal
ovulation are possible after cryopreservation and trans-
plantation of whole ovaries in sheep.
Imhof et al. [10] reported pregnancy and live birth by
orthotopic microvascular re-anastomosis of whole frozen-
thawed sheep ovaries. These authors used a slow freezing/
rapid thawing method for the cryopreservation of the
intact ovaries with vascular pedicles following a perfusion
step with cryoprotectants. However, follicular loss was
higher as revealed by histological examination (follicular
survival rate ~4.3%). The authors re-emphasize the need
for further refinements in cryopreservation regimens so as
to increase the follicular survival rate.
Transplantation options
To date various techniques for transplantation of ovarian
cryopreserved tissue exist. Autotransplantation would be
beneficial as it would avoid dealing with immunosup-
pressant treatments. The most advantageous option
would be orthotopic autotransplantation as it might fur-
thermore lead to natural conception, while heterotopic
transplantation is another autotransplantation alterna-
tive. Both allotransplantation (same species) as well as
xenografting into animals of a different species also pro-
vides further options and treatments.
Successful animal experiments were performed in the
early 90's in which transplantation of cryopreserved-
thawed ovarian cortical strips led to follicular survival and
endocrine function, as well as pregnancy and delivery
[11,12]. The first human pregnancy by cryopreserved
ovarian cortex and transplantation was recently reported
[13]. In 2005, Meirow et al. also reported a live birth after
orthotopic autotransplantation of cryopreserved ovarian
tissue in a patient with POF after chemotherapy [14].
Because of the limitations (ischemic injury, delays in neo-
vascularization) of fresh and cryopreserved-thawed ovar-
ian cortical strips, intact ovarian tissue grafting in
conjunction with cryopreservation is thought to be poten-
tially a better option to preserve fertility. Until now,
autotransplantation procedures have been limited almost
exclusively to non-vascular cortex segments grafted to
either orthotopic or heterotopic locations. The disadvan-
tage of non-vascular grafts is that they often sustain signif-
icant ischemic injury until tissue revascularization takes
place [15]. The reduction of the ischemic time-interval
after re-implantation is therefore crucial for the reproduc-
tive potential of the transplants. In general a large number
of follicles (up to two-thirds) are lost shortly after trans-
plantation of cryopreserved ovarian tissue. This loss is
unlikely to be due to freezing and thawing, but more
likely caused by post-transplantation ischemia. Israely et
al. [16] have shown that a reduction in ischemic damage
is possible by transplantation into granulation tissue.
They have shown that transplantation into angiogenic
granulation tissue, created during wound healing, short-
ened the ischemic period by 24 hours and significantly
increased the pool of healthy primordial follicles and the
perfused area of the transplanted grafts.
A vascular transplant has been suggested as the most logi-
cal approach compared with transplantation of ovarian
cortical tissue. Despite the technical difficulty of the trans-
plantation procedure, it grants immediate blood supply to
the transplant, thus minimizing ischemic injury.Reproductive Biology and Endocrinology 2008, 6:47 http://www.rbej.com/content/6/1/47
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Safety issues and future prospects
Current cryopreservation protocols appear to affect crucial
interactions between the oocyte and granulosa cells, espe-
cially the crucial communications via transzonal proc-
esses containing filamentous actin (TZPs-Act). A study
comparing the efficacy of cryoprotective agents like dime-
thyl sulfoxide (DMSO) and glycerol on gap junctional
communications during ovarian tissue cryopreservation
has shown that DMSO is superior to glycerol in maintain-
ing a higher post-thaw TZPs-Act density because of its
higher tissue permeation coefficient [17]. Both cryopreser-
vation and cryoprotectant exposure have been shown to
compromise the integrity of the granulosa-oocyte inter-
face, suggesting that further optimization of cryopreserva-
tion protocols is still required to curtail the disruption of
cellular communication routes in the ovary. Any disrup-
tions in communication pathways required for the inte-
gration of oogenesis and folliculogenesis have been
shown to result in either inappropriately timed or defec-
tive chromatin remodeling that leads to specific defects in
meiotic competence [18]. One of the consequences of a
loss in coordination is believed to be caused by the failure
to appropriately regulate gene expression in the develop-
ing oocyte and/or the acquisition of meiotic competence.
The need to sustain and coordinate these processes during
normal ovarian cyclicity or during ovarian stimulation or
any in vivo/ex vivo manipulations like ovarian tissue cryo-
preservation and transplantation is tantamount to the
production of developmentally competent oocytes for use
in assisted reproduction technologies.
Experimental evidences indicate that damage due to extra-
cellular ice is the single most serious obstacle to the exten-
sion of cryopreservation techniques to multicellular
systems [19]. The ice-free vitrification method of ovarian
tissue preservation may prevent intravascular ice forma-
tion, which leads to failure of blood supply following
grafting and vascular anastomosis. However, one major
concern is the temperature gradient during the warming
step that might induce damages in vitrified bulky samples
like ovarian tissue and whole organs. The possibility of
using electromagnetic heating is being studied for this
purpose [20]. Several anti-freeze proteins and ice blockers
have been shown to reduce the critical warming rate and
thereby avoid the devitrification effect of some cryopro-
tectant solutions [21]. An important step in designing a
vitrification procedure is to measure the penetration of
the vitrification solutes throughout the system and assess
the cell-volume response to the changes in osmolarity that
will be caused by the added solutes [22]. Rahimi et al. [23]
compared necrosis in human ovarian tissue after conven-
tional slow freezing or vitrification and subsequent
xenotranplantation in severe combined immunodefi-
ciency (SCID) mice. There was no significant difference in
necrosis between the groups.
Development of new cryo-chambers, vascular perfusion
systems and warming devices to avoid de-vitrification or
recrystalization, as well as improving cryopreservation
protocols for the intact ovary, are considered vital direc-
tions in ongoing research to make the transplantation of
an entire ovary a realistic objective [22,24]. A novel
method of direct cover vitrification has been shown to
increase follicular viability and pregnancy capability in
mice ovarian tissue [25]. It uses less concentrated cryopro-
tectant and maximizes the cooling rate by utilizing direct
cover with liquid nitrogen. Migishiga et al. [26] developed
a different protocol for the cryopreservation of whole ova-
ries by vitrification. DAP 213 (2 M DMSO, 1 M acetamide
and 3 M propylene glycol) was used as cryoprotectant
after a prior equilibration in 1 M DMSO at 5°C. Even
though various strategies have been reported in the litera-
ture for freezing of ovaries, the oocyte competence and
developmental potential after re-transplantation seems
low. Further refinement in technology, especially ice-free
vitrification, is warranted. It is suggested that the cryop-
reservation procedure may have some negative effects
even on the residual recipient's ovary as well as on the
ovarian graft and that the cryoprotectant remaining in the
transplanted graft might be one of the factors causing
these deleterious effects [26]. Based on the reports show-
ing improvements during oocyte cryopreservation using
higher sucrose concentration, Bianchi et al. [27] studied
the effect of different sucrose concentration during ovar-
ian tissue freezing. Human oocytes were cryopreserved
using a modified slow-cooling protocol involving 1.5
mol/l propane-1,2-diol (PrOH) and 0.2 mol/l sucrose
during dehydration, while rehydration was conducted
applying decreasing concentrations of PrOH and 0.3 mol/
l sucrose. Increased oocyte survival rates were achieved by
these moderately high sucrose concentrations in the freez-
ing and thawing solutions. This also ensures elevated suc-
cess rates in terms of fertilization, embryo development
and clinical outcome. The use of 0.3 mol/l sucrose
showed a smaller percentage of damaged germ cells than
0.2 mol/l sucrose, and therefore was less detrimental to
the thawed ovarian tissue based on their electron micro-
scopic histological observations.
According to the Practice Committee of the ASRM [28],
ethical and safety issues are to be considered at different
levels when applying ovarian tissue cryopreservation and
transplantation in patients [29] as this procedure can lead
to reintroducing malignant cells, as mentioned previ-
ously. The safety of this procedure can be compromised
by the transmission of lymphoma via grafting of ovarian
tissue from diseased donor mice to healthy recipients
[30]. Intensive collaboration between oncologists and fer-
tility-preservation specialists is required for correct esti-
mation of risk for each patient. Though in its infancy,
xenografting [31] or in vitro follicle culture could be futureReproductive Biology and Endocrinology 2008, 6:47 http://www.rbej.com/content/6/1/47
Page 5 of 10
(page number not for citation purposes)
solutions for individuals at risk of cancer re-transmission.
Blastocyst development and birth of pups derived from
vitrified preantral follicles and ovarian tissue have been
reported recently [32,33]. Kagawa et al. [34] also reported
the birth of 10 healthy mouse pups derived from oocytes
obtained from preantral follicles using adult ovarian tis-
sue vitrification and allotransplantation in SCID mice. An
apoptotic and necrotic pathway of cellular reduction has
been reported in cryopreserved mouse ovaries. It has been
reported that cryopreserved sheep preantral follicles
underwent growth in vitro but that freezing/thawing spe-
cifically affected gap junctional permeability and
impaired the progression of regulative processes; such as
the acquisition of a specific oocyte chromatin configura-
tion [35].
Today's technological advances allow for a complete
genetic assessment of cells and tissues through microar-
ray-based global gene expression patterns and MALDI-
TOF- based proteomic studies. Future research should uti-
lize these novel and potential technologies to unravel the
molecular information of germ cells as well as somatic
cells in ovarian tissues post-cryopreservation and -trans-
plantation to nude mice that can support the growth of
such tissues in a synchronous and coordinated way. Kim
et al. [36] have studied the proteome of cryopreserved
bovine ovarian tissue and shown alterations in protein
profiling and expression in ovarian grafts after transplan-
tation. The most significant of the identified proteins after
transplantation were those related to tissue survival and
metabolism, such as actin and laminin, and antioxidant
properties (glutathione S-transferase). Glutathione-S-
transferase is an enzyme that is usually upregulated in oxi-
dative stress and mRNA; it also has been shown to be
upregulated in mouse embryos under cold stress response
[37]. Among the slow-freeze and vitrification groups, the
change in protein profile of the vitrified and transplanted
ovarian tissue was more consistent with that of the fresh
controls [36] and, therefore, possibly holds the key for
optimizing this technique. The latest technical develop-
ments such as laser capture microdissection can be used to
obtain pure cancer cells from fresh-frozen cancer tissue
and the surrounding environment, thus providing an
accurate snapshot of the tumor and its microenvironment
in vivo. Silasi et al. [38] reported a new approach to isolate
pure cancer cell populations and evaluate protein expres-
sion. The process includes immunocytochemistry, laser
microdissection, and western blot analysis. Using this
technique, it is suggested that proteins such as X-linked
inhibitor of apoptosis protein and Fas ligand could be
detected with as little as 1000 cells. These approaches
might be useful in detection of any cancer cells in frozen-
thawed ovaries prior to transplantation back to the
patient.
Research and development of technology to cryopreserve
whole organs, as well as surgical techniques for the
autotransplantation of an entire ovary with its vascular
pedicle, are being intensely pursued by several research
groups. This could lead to the transplantation of intact
ovaries with microvascular anastomosis carried out to
restore immediate vascularization and minimize post-
transplantation ischemia, responsible for the reduction in
follicular density.
According to Bedaiwy [3] the ultimate challenge to
achieve a successful ovarian implant is for the ovarian
fragment or intact ovary to 1) survive the freeze-thaw
trauma with minimal damage to the follicular structure,
2) establish blood supply immediately upon transplanta-
tion, 3) regain reproductive and endocrine function and
4) survive for a considerable time.
In vitro growth of primordial follicles and in vitro 
maturation of oocytes from antral follicles
As a consequence of radiation and chemotherapy, many
females suffer from POF and premature menopause. Cry-
opreservation of mature oocytes has shown limited suc-
cess, which means that very few options for putative
fertility restoration are available to these patients [39]. In
fetal and adult human ovaries, most of the follicles
remain primordial [40] and, therefore, immature oocytes
are regularly available and would be the easiest and most
abundant source of female gametes. However, they still
must grow and undergo maturation in order to become
fertilizable, and this has to be obtained in vitro.
Keeping pace with efforts to refine in vitro fertilization
(IVF) techniques, active research is continuing in the area
of folliculogenesis and in vitro oocyte maturation.
Progress in this field will benefit patients who have stored
ovarian tissues prior to debilitating cancer treatments.
This also may allow patients a realistic chance of conceiv-
ing a child at an advanced age (e.g., career-orientated
women who wish to postpone childbearing) if ovarian
material was harvested from the ovary at an early age and
stored. Healthy immature oocytes can be retrieved at a
later stage and matured in vitro for IVF. Moreover, com-
pared to conventional IVF, the advantages of this
approach include no hormonal down-regulation or hor-
mone injections in regularly cycling women; minimal
stimulation with follicle stimulating hormone (FSH) in
women with polycystic ovaries (PCO); no ovulation injec-
tion, thereby minimizing any side effects and discomforts;
and reduction in treatment span and interference with
daily life combined with less emotional stress. IVM of pri-
mordial follicles also would avoid the possible risk of re-
transmission of some cancers, such as hematological
malignancies [41] and breast cancer [42], by ovarian grafts
as oocytes do not contain cancerous cells. However, theReproductive Biology and Endocrinology 2008, 6:47 http://www.rbej.com/content/6/1/47
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growth and IVM of primordial follicles remains a major
challenge for reproductive biologists (Figure 2).
In vitro follicle culture
The ovarian physiology of mice and knockout mice mod-
els has been studied extensively, and in vitro culturing of
distinct stages of preantral and antral follicles has pro-
vided much information on somatic and germ cells inter-
actions during growth and maturation [43,44]. Only a
single offspring has been produced so far in the mouse
model by IVF after the growth and maturation of primor-
dial follicles in vitro [45,46]. A normal expression pattern
of growth differentiation factor (GDF-9) and anti-Mülleri-
an hormone has been reported in human follicles cul-
tured  in vitro after freeze-thaw cycles [47]. This study
further point out that a defined serum free medium could
support transition from resting to growing follicles lead-
ing to the development of secondary follicles during the in
vitro follicle culture of frozen thawed human ovarian tis-
sues.
Primordial follicles can be isolated from either fresh or
cryopreserved ovarian tissues. These follicles typically
contain a small oocyte arrested at the diplotene stage of
the meiosis and surrounded by a single layer of flattened
pregranulosa cells and a basement membrane. Primordial
follicles are located in a narrow cortical band in primate
ovaries under a poorly vascularized tunica albuginea. A
cortical biopsy of ~1 mm thick can yield sufficient follicle-
rich region without much bleeding as prominent blood
vessels lie deep in the medulla. Isolation of primordial
follicles involves either mechanical or enzymatic treat-
ment. Avoiding damage to the basement membrane and
other intra- follicular compartments is a major challenge
during the harvesting of these follicles, and further in vitro
developmental potential largely depends on a successful
harvesting procedure. Follicles also can be grown in organ
explants until they have grown to a stage at which they can
be isolated as granulosa-oocyte complexes and transferred
to either collagen membrane or three-dimensional culture
systems. Otherwise, cultured organ explants can be trans-
planted to host animals to complete the follicular devel-
opment. As recently demonstrated [48], liberase
treatment allows the isolation of highly viable follicles
with an unaltered morphology and ultra structure. This
enzyme preparation is said to be a promising alternative
to collagenase preparations for the reproducible isolation
of intact primordial follicles for culture and grafting pur-
poses. The same authors recently have shown that isolated
human follicles are able to survive and grow after
xenografting [49], as they observed well-structured,
IVM and cryopreservation of oocytes Figure 2
IVM and cryopreservation of oocytes.
 
Figure 2: IVM and cryopreservation of oocytes 
Advantages 
Immediate harvesting in case of IVM (can start treatment without delay) 
No male partner/gamete donor needed 
Complete gonadotoxic and or ionizing radiation treatment without exposing gametes 
Preserve fertility 
Avoid risk of cancer re-transmission 
IVM suitable for prepubertal girls 
IVM is best suited for patients with polycystic ovaries containing numerous small antral 
follicles 
Oocyte cryopreservation becoming more successful 
Disadvantages 
Oocytes sensitive to cryoinjury 
Requires surgical procedures for tissue harvesting or follicle aspiration 
Oocyte retrieval requires 2 to 3 weeks for induction of multiple follicular maturation (place 
patient at risk of ovarian hyperstimulation syndrome) 
Oocyte retrieval not suitable for prepubertal girls 
IVM has low success rate Reproductive Biology and Endocrinology 2008, 6:47 http://www.rbej.com/content/6/1/47
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stroma-like tissue of human origin around the isolated
follicles one week after grafting.
For domestic animals and humans, the technology is still
far from successful; there are only a few reports of limited
success using in vitro culture of large preantral follicles that
have progressed further developmentally [50,51]. The
large, preantral follicles contain oocytes that are almost
fully grown; however, the meiotic competence of these
follicles remains low, indicating that the culture methods
require optimization. As the store of female gametes is
maintained within the primordial follicles, the real chal-
lenge is to establish the culturing of primordial follicles.
Unraveling the regulation of the transition from primor-
dial to primary follicle is the key to accessing an almost
unlimited source of oocytes for biomedical use.
Each species has its own specific developmental timeline.
In rodents (mice, rats), the time span between initiation
of follicle growth and formation of the antral cavity is a
few weeks and in large domestic animals it takes several
months. During the preantral growth phase, the oocyte
grows rapidly and reaches almost its maximum volume
when the first accumulation of fluid is observed within
the granulosa cell mass. In humans, Gougeon [52] esti-
mated that the growth phase from primordial to primary
follicle in humans takes > 120 days. Once in the growing
pool, the follicle requires 65 days to reach the early antral
phase (follicle of 2–5 mm diameter). At this point it
becomes dependent on gonadotrophins for further
growth.
Factors regulating ovarian follicle growth, death and
recruitment still need to be elucidated fully. Hence,
choosing an artificial culture system will always mean a
compromise. When the aim is to mimic normal physiol-
ogy and to culture the follicles as multilayered spheres, the
supply of essential nutritional and physical factors to the
inner centre of the structure becomes critical [53]. One
potential limitation of the conventional culture systems is
the disruption of follicle architecture that can occur when
follicles are cultured on a two-dimensional substrate [54].
The change in follicle morphology may alter the paracrine
signaling that is critical to follicle maturation because the
altered cell-cell orientation could result in diffusion of
paracrine signals away from the target cells. The culture
environments and media compositions tested to date
appear incapable of creating the right environment for
inducing growth changes that are compatible with physi-
ological growth patterns. It was found that FSH and insu-
lin [55,56] promote the growth and survival of the
follicles as well as GDF- 9 [57]. Growth factors such as
cGMP also showed improvement in follicle survival [58].
The optimal culture media for growth promotion may
need to be very rich in supplements and be species-spe-
cific. Using different compositions of media sequentially
for every follicular stage also may be necessary until a
mature, healthy and fertilizable human oocyte is obtained
[59].
The recent application of tissue engineering technologies
to follicle culture has opened up new insights into follicle
physiology in vitro and yielded favorable results [60]. The
novel three-dimensional culture system, in which individ-
ual immature mouse granulosa-oocyte complexes or
intact follicles are encapsulated within alginate beads, is
one such system [61,62]. Alginate is a linear polysaccha-
ride derived from algae and composed of repeating units
of β-d-mannuronic acid and α-L-glucuronic acid and gels
by ionic cross linking of the glucuronic residues [63]. In
this system, the alginate matrix provides a mechanical
support for the follicle as it increases in size, allowing
examination of the role of various factors in follicle
growth while maintaining an in vivo-like morphology.
Additionally, encapsulating the follicle within a three-
dimensional matrix allows for studying the interactions of
the outer layers of somatic cells and insoluble factors,
such as the extracellular matrix, which direct follicle
growth and maturation. Culture systems like the three-
dimensional one that can be tailored to the developmen-
tal stage of the follicle will be especially critical for trans-
lation to human follicles, which require several months to
mature [64].
The developmental transition of primordial (oocytes in
late diplotene stage) to primary follicles is characterized
by a cuboidal appearance of the granulosa cells (a process
of 120 days) from a flattened nature and initial growth of
the nucleus. These changes, however, occur within a few
days in vitro [65]. The regulatory mechanisms that coordi-
nate oocyte growth and cell division in the surrounding
somatic cells are largely unknown. The encouraging
results with three-dimensional culture of murine preant-
ral follicles along with extra-cellular matrix and activin-A
emphasize that such an environment provides a sufficient
in vitro milieu for follicle growth and survival [66].
There is ample opportunity for improvement in this area
as the technical requirements and the selection of essen-
tial biochemical determinants for the preantral stages of
follicle development need to be characterized precisely.
Mapping these stage-related biochemical determinants of
follicle growth requires investigation of follicles at well-
characterized growth stages using new, powerful molecu-
lar biology techniques such as gene chip technology, pro-
teomics and metabolomics. Interaction among
professionals in the fields of cell culture, biomedical engi-
neering and molecular biology will lead to more rapid
advances in this area.Reproductive Biology and Endocrinology 2008, 6:47 http://www.rbej.com/content/6/1/47
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Cryopreservation of ovarian tissue has been reported to
delay the development of preantral follicles during in vitro
culture. Choi et al. [67] studied the effects of cryopreserva-
tion on the proliferation of granulosa cells during culture
of mouse preantral follicles to understand the underlying
mechanism of delayed follicular development. He found
a significant reduction in granulosa cell proliferation of
the cryopreserved preantral follicles compared to that of
the fresh controls. Moreover, expressions of cyclin D2,
Cdk4, cyclin E and Cdk2 also were reduced in the vitrified
ovarian tissues at 0 and 24 h after culture. It is apparent
from this study that the granulosa cell death and tempo-
rary suppression of granulosa cell proliferation through
cell cycle regulators might account for delay in preantral
follicle development following cryopreservation regimes.
Current investigations show that the viability of caprine
preantral follicles can be preserved best after solid surface
vitrification in a mixture of sucrose and ethylene glycol
followed by washes in medium containing sucrose, as
opposed to the conventional vitrification procedure [68].
Choi et al. [69] evaluated the effect of cryopreservation
(slow freezing and vitrification) on the development of
frozen-thawed mouse primordial follicles. A significant
reduction was noted in the developmental rate after in
vitro  culture of primordial follicles derived from both
types of freezing methods, with a slight reduction in the
mRNA expression (GDF-9, inhibin-alpha subunit and
ZP3) levels than the fresh controls after five days of in vitro
culture. Continuous agitation while culturing frozen-
thawed ovarian issues have been shown to reduce degen-
eration of follicles [70].
In vitro maturation of oocytes from antral 
follicles
Currently more than 300 healthy infants have been born
following immature oocyte retrieval and IVM. Follow-up
studies have reported no major concerns about the preg-
nancies, deliveries or health of the babies. Collection of
small antral follicles with in vitro oocyte maturation is
entering the mainstream of assisted reproductive technol-
ogies and is considered a better option for patients having
polycystic ovarian syndrome (PCOS).
PCOS is characterized by abnormal endocrine parame-
ters, anovulation, sonograms showing multiple antral fol-
licles within the ovarian cortex and, frequently, infertility.
Priming of ovarian immature oocytes with follicle-stimu-
lating hormone or human chorionic gonadotropin prior
to immature oocyte retrieval has been shown to improve
oocyte maturation rates and embryo quality as well as
pregnancy rates in these patients. Several factors deter-
mine the successful outcome with IVM of antral follicles.
The size of follicles may be an important factor for subse-
quent embryonic development, but the developmental
competence of oocytes originating from the small antral
follicles is not adversely affected by the presence of a dom-
inant follicle. Oocyte maturation (nuclear as well as cyto-
plasmic) also is affected profoundly by culture conditions.
In general, the clinical pregnancy and implantation rates
have reached 30–35% and 10–15%, respectively in infer-
tile women with PCO or PCOS [71]. However, a recent
report by Buckett et al. [72], which showed a higher rate of
clinical miscarriage after IVM compared with IVF and
intracytoplasmic sperm injection, warrants more rigorous,
controlled studies on the efficacy of IVM, especially in
PCOS. The possible long-term effects of IVM on the health
and development of children also needs further study. At
this juncture, it is imperative to say that couples should be
counseled carefully about the current uncertainties
involved in the assisted conception modalities used.
Conclusion
The literature shows a substantial body of relevant works
in organ cryopreservation, as reviewed by Fahy et al. [73],
and this may pave the way for a successful development of
cryopreservation regimens for ovarian tissue by vitrifica-
tion. The ability to consistently recover rabbit kidneys
after cooling to core temperatures of about -45°C with
subsequent long-term life support function after trans-
plantation constitutes a major achievement and gives the
strongest evidence to date that the vitrification of whole
organs may be achievable [73]. Physical studies seem
indispensable for the progress of organ cryopreservation
by vitrification [74].
As ovarian tissue cryopreservation enters the mainstream
of assisted reproductive technology, the study of follicle
biology and the search for an ideal in vitro follicle culture
system are of major interest. One main concern with
autografting of frozen-thawed ovarian grafts from cancer
patients is the risk of re-introducing cancer cells. In this
regard, frozen-thawed follicle culture is a more attractive
goal in the long term because it would eliminate any risk
of re-implanting any residual cancer cells and could in
theory, produce more mature oocytes by avoiding follicle
wastage created by ischemia or normal atresia. Despite the
fact that follicle culture techniques have improved signif-
icantly due to ongoing active research, concerns about the
formation and integrity of imprints in oocytes growing
and ripening in vitro remain because defects could mani-
fest as embryonic death or unhealthy offspring. The pre-
mature death and abnormalities of the first mouse ever
produced from a primordial follicle in vitro serves as a
warning and challenge for cryobiologists [46].
In conclusion, research should focus on refining cryop-
reservation and transplantation protocols to prevent the
destructive effect of ischemic injury on follicular viability.Reproductive Biology and Endocrinology 2008, 6:47 http://www.rbej.com/content/6/1/47
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The use of vascularized grafts and selection of an appro-
priate transplantation site may offer a plausible solution.
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